anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Multidrug-resistant (MDR) bacteria pose a significant challenge to the treatment of infectious diseases. Of particular concern are members of the Klebsiella pneumoniae species complex (KpSC), which are frequently associated with hospital-acquired infections and have the potential to spread outside hospitals via wastewaters. In this study, we aimed to investigate the occurrence and phylogenetic relatedness of MDR KpSC from patients with urinary tract infections (UTIs), hospital sewage, municipal wastewater treatment plants (mWWTPs) and surface waters and to evaluate the clinical relevance of the KpSC subspecies.
METHODS: A total of 372 KpSC isolates resistant to third-generation cephalosporins and/or meropenem were collected from patients (n = 130), hospital sewage (n = 95), inflow (n = 54) and outflow from the mWWTPs (n = 63), river upstream (n = 13) and downstream mWWTPs (n = 17) from three cities in the Czech Republic. The isolates were characterized by antimicrobial susceptibility testing and whole-genome sequencing (Illumina). The presence of antibiotic resistance genes, plasmid replicons and virulence-associated factors was determined. A phylogenetic tree and single nucleotide polymorphism matrix were created to reveal the relatedness between isolates.
RESULTS: The presence of MDR KpSC isolates (95%) was identified in all water sources and locations. Most isolates (99.7%) produced extended-spectrum beta-lactamases encoded by blaCTX-M-15. Resistance to carbapenems (5%) was observed mostly in wastewaters, but carbapenemase genes, such as blaGES-51 (n = 10), blaOXA-48 (n = 4), blaNDM-1 (n = 4) and blaKPC-3 (n = 1), were found in isolates from all tested locations and different sources except rivers. Among the 73 different sequence types (STs), phylogenetically related isolates were observed only among the ST307 lineage. Phylogenetic analysis revealed the transmission of this lineage from patients to the mWWTP and from the mWWTP to the adjacent river and the presence of the ST307 clone in the mWWTP over eight months. We confirmed the frequent abundance of K. pneumoniae (K. pneumoniae sensu stricto and K. pneumoniae subsp. ozaenae) in patients suffering from UTIs. K. variicola isolates formed only a minor proportion of UTIs, and K. quasipneumoniae was not found among UTIs isolates; however, these subspecies were frequently observed in hospital sewage communities during the first sampling period.
CONCLUSION: This study provides evidence of the transmission and persistence of the ST307 lineage from UTIs isolates via mWWTPs to surface waters. Isolates from UTIs consisted mostly of K. pneumoniae. Other isolates of KpSC were observed in hospital wastewaters, which implies the impact of sources other than UTIs. This study highlights the influence of urban wastewaters on the spread of MDR KpSC to receiving environments.
PURPOSE: An oral cavity cleaning unit is provided to easily remove solid foreign materials in addition to liquid foreign materials from an oral cavity and to keep the oral cavity clean. CONSTITUTION: An oral cavity cleaning unit includes a body part(10) and a wiping part(20). The body part has a gripping part. The wiping part is soft and is arranged at one side of the body part. Oral cavity cleaning liquid is absorbed in the wiping part, and the wiping part wipes the inner wall part of the oral cavity. The upper side of the wiping part is in the shape of waves such that the teeth and the palate of the oral cavity are cleaned.
A single chain T cell receptor (scTCR) comprising an a segment constituted by a TCR .alpha. chain variable region sequence fused to the N terminus of a TCR .alpha. chain constant region extracellular sequence, a .beta. segment constituted by a TCR .beta. chain variable region fused to the N terminus of a TCR .beta. chain constant region extracellular sequence, and a linker sequence linking the C terminus of the .alpha. segment to the N terminus of the .beta. segment, or vice versa, the constant region extracellular sequences of the .alpha.and .beta. segments being linked by a disulfide bond, the length of the linker sequence and the position of the disulfide bond being such that the variable region sequences of the .alpha. and .beta. segments are mutually orientated substantially as in native .alpha..beta. T cell receptors. Complexes of two or more such scTCRs, and use of the scTCRs in therapy and in various screening applications are also disclosed.
PURPOSE: To obtain the subject DNA useful for simply and surely diagnosing an insulin-nondependent diabete from an insulin-nondependent diabete patient caused by the abnormality of an insulin receptor. CONSTITUTION: The mutated human insulin receptor DNA wherein a base sequence coding the No. 831 Thr in a human insulin receptor DNA is mutated into a base sequence coding Ala and/or a base sequence coding the No. 1334 Try is mutated into a base sequence coding Cys. The mutated human insulin receptor DNA is obtained by breeding all 22 exon genes in the insulin receptors of insulin-nondependent diabete patients by a PCR method, inserting the bred exon genes into pUC 19 vectors, and subsequently determining the DNA sequences, and can be synthesized by a solid phase method, etc. The mutated human insulin receptor DNA causes the qualitative mutation of at least approximately 6% of insulin-nondependent diabete crisis-causing genes.
This invention relates to a biological process for the biosynthesis of two intracellular solutes identified as di-mannosyl-di-myo-inositol phosphates and 1,3'-di-myo- inositol phosphate. These have been identified in the hypothermophilic bacteria Thermatoga maritima and Thermatoga neapolitana (growth Topt 80 degree C) during growth at supraoptimal temperatures in complex medium. The environmental conditions necessary for their accumulation in high concentrations indicate that these new compatible solutes can have an effect in protecting macromolecules (specifically biocatalysts) and cells against operations involving heating, drying or freezing. Di-mannosyl-di-myo-inositol phosphate and 1,3'-di-myo- inositol phosphate can be used in enzyme catalysed processes at high temperatures or when these are performed in the presence of chemical denaturing agents such as detergents, organic solvents, oxidizing agents or caotropic agents such as urea or guanidine chloride with the intention of stabilizing their activity over the short and long term. Di-mannosyl-di-myo-inositol phosphate and 1,3'-di-myo- inositol phosphate can also be used to stabilize liposomes and other membrane systems used in the microencapsulation of drugs and other compounds used in the pharmaceutical, cosmetics, detergents and other industries. <IMAGE> Di-mannosyl-di-myo-inositol phosphate and 1,3'-di-myo- inositol phosphate can also be used during the drying of proteins and whole cells for transport and prolonged conservation and also as adjuvants for the preservation of microorganism strains or animal and plant cell lines, as well as perfused organs by freeze-drying or at low temperatures.
A system includes an initialization module, an imaging module, an alignment module, a processing module, and a setup module. The initialization module obtains patient parameters of the patient as well as surgical and surgeon parameters. An initialization module selects a first setting for the x-ray source based on patient parameters, surgical parameters, and surgeon parameters. An image module obtains a first sample set of images of a region of interest of a patient and a master sample set of images. A first set of samples is acquired as a result of the x-ray source operating according to a first setting. The alignment module aligns the first set of samples with the master set of samples. A processing module processes pixel data corresponding to a result of the alignment based on the pixel parameter or one of the patient parameters. The settings module adjusts the first settings to provide updated settings. The x-ray dose associated with the updated setting is less than the x-ray dose associated with the first setting.
A method and composition are disclosed for transfecting eukaryotic cells using a DNA segment coupled to a site-specific chromosome-binding polypeptide. The polypeptide-DNA conjugate is referred to herein as a polypeptide-linked-rDNA (PLR) molecule. One example of a PLR molecule comprises a DNA segment containing a nucleotide sequence from a normally functioning human gene, coupled by means of a covalent crosslinking reagent to a site-specific chromosome-binding polypeptide (such as a transcription regulating polypeptide that binds to a specific nucleotide sequence in chromosomal DNA). After the PLR molecule enters the cytoplasm of a cell, such as by electroporation, the chromosome-binding polypeptide enables transport of the PLR molecule through the cytoplasm and into the nucleus, using a nuclear localization sequence (NLS) domain of the polypeptide. Inside the nucleus, the polypeptide scans the chromosomes until it binds to a specific chromosomal binding site. This positions the DNA segment of the PLR molecule near a target sequence (such as a defective gene) in the chromosome. The desired DNA segment contained in the PLR molecule has sufficient nucleotide sequence homology with the target gene to enable a recombination event to replace the target gene sequence with the desired gene sequence.
The frailty index (FI) uses a deficit accumulation approach to derive a single, comprehensive, and replicable indicator of age-related health status. Yet, many researchers continue to seek a single "frailty biomarker" to facilitate clinical screening. We investigated the prognostic accuracy of 70 individual biomarkers in predicting mortality, comparing each with a composite FI. A total of 29,341 individuals from the comprehensive cohort of the Canadian Longitudinal Study on Aging were included (mean, 59.4 ± 9.9 years; 50.3% female). Twenty-three blood-based biomarkers and 47 test-based biomarkers (e.g., physical, cardiac, cardiology) were examined. Two composite FIs were derived: FI-Blood and FI-Examination. Mortality status was ascertained using provincial vital statistics linkages and contact with next of kin. Areas under the curve were calculated to compare prognostic accuracy across models (i.e., age, sex, biomarker, FI) in predicting mortality. Compared to an age-sex only model, the addition of individual biomarkers demonstrated improved model fit for 24/70 biomarkers (11 blood, 13 test-based). Inclusion of FI-Blood or FI-Examination improved mortality prediction when compared to any of the 70 biomarker-age-sex models. Individual addition of seven biomarkers (walking speed, chair rise, time up and go, pulse, red blood cell distribution width, C-reactive protein, white blood cells) demonstrated an improved fit when added to the age-sex-FI model. FI scores had better mortality risk prediction than any biomarker. Although seven biomarkers demonstrated improved prognostic accuracy when considered alongside an FI score, all biomarkers had worse prognostic accuracy on their own. Rather than a single biomarker test, implementation of routine FI assessment in clinical settings may provide a more accurate and reliable screening tool to identify those at increased risk of adverse outcomes.
FIELD: veterinary science. SUBSTANCE: invention relates to production of antiparasitic preparations based on avermectins prepared by microbiological synthesis. Antiparasitic veterinary injection preparation comprises an active component and neutral solvent. Active component is avermectin complex and solvent is mixture of ethanol, polyethylene glycol, polyvinylpyrrolidone and water taken in the following ratio of components, wt.-%: avermectin complex, 0.9-1.1; polyvinylpyrrolidone, 0.5-8.0; polyethylene glycol, 42-60; 96% ethyl alcohol, 30-42; water for injection, 8-10. For different conditions it is possible to select one of three complexes of avermectins differing by the content of individual components. Antiparasitic activity of preparation exceeds 95%. EFFECT: enhanced effectiveness of preparation. 4 cl, 3 tbl, 1 ex
In this arm, the subjects will perform an observational task - observation of hand movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
This is a single-arm, open label, pilot study of 8 subjects with HFpEF. The subjects will undergo screening tests (exercise stress echo and blood work) to evaluate for potential exclusion criteria and provide familiarization to the exercise protocol. Those included will undergo an echocardiogram and invasive cardiopulmonary exercise test. This involves placement of a right heart catheter in the pulmonary artery and undergoing seated, upright exercise. During the exercise test, the subject's oxygen uptake (VO2), intra-cardiac pressures (right atrial pressure, pulmonary capillary wedge pressure) and cardiac output (Qc) will be measured. The subject will take a dose of empagliflozin in the lab and wait for at least 60 minutes. They will repeat a shortened version of the exercise test in the afternoon. After baseline testing, each subject will take 10mg empagliflozin daily for 12 weeks. They will have repeat blood work (specific electrolytes and renal function) 30 days after starting medication to screen for renal injury. After 12 weeks, they will return for another invasive cardiopulmonary exercise test and echocardiogram.
Sixty patients with periorbital hyperpigmentation were enrolled, patients were divided into 2 groups; 30 each. clinical grading according to sheth et al.,2014 , dermoscopic evaluation, visual analogue score (VAS) and DLQI were done at week 0. Group A one side was treated with vit.c 20% + microneedling, other side saline+ microneedling (placebo). group B one side was treated with tranexamic acid 5mg/ml + microneedling, other side saline+ microneedling (placebo). A total of 4 sessions were done 2 weeks apart and follow up was one month after the last session (week 10) at which patient was evaluated using above mentioned parameters in addition to evaluation by 2 blinded investigators. At week 10 there was significant improvement of clinical grading and as evaluated by blinded investigators, VAS, DLQI, significant dermoscopic improvement in both vascular and pigmentary components of dark halos in sides treated with vit c and tranexamic acid compared to placebo but there was no statistically significant difference between both groups. The study concluded that tranexamic acid is a new safe effective modality in treatment of periorbital hyperpigmentation with results comparable to vitamin C.
Clinical assessment of severity of mitral stenosis depends on both the presence of symptoms and mitral valve area . Evaluation of mitral valve area with transthoracic echocardiography maintains rapid, accurate analysis of valve disease and serves as a practical gold standard for clinical evaluation. Cardiac magnetic resonance imaging (CMRI) is a recently used method that allows to evaluate cardiac structures and function noninvasively. Direct visualization of valve area with CMRI is also possible and it has been shown that the valve area assessed by CMRI planimetry correlates reliably with the invasive assessment. Velocity-encoded cardiac magnetic resonance imaging can be used to quantify mitral valve area. The objective of this study was to evaluate mitral valve area with CMRI and compare it with echocardiographic methods including 2D planimetry, Doppler continuation equation and Doppler pressure half-time
Chicken II and salmon GnRH analog decapeptides resistant to degradation by peptidase incorporating D-arginine, D-leucine, D-tBu-Serine, D-Trp or other active D amino acids at position 6 and ethylamide, aza-Gly-amide or other Gly amide at position 10. The analogs demonstrate preferential binding to male and female reproductive system GnRH receptors. Biopotency is greater within the reproductive system than at the pituitary. These non-mammalian GnRH analogs may be used in pharmaceutical preparations, and specifically in various treatment methods as a contraceptive or post-coital contraceptive agent. The non-mammalian GnRH analogs are also provided in pharmaceutical preparations that may be used clinically for maintaining pregnancy when used in very low doses and administered in pulsatile fashion, as well as in preparations for the treatment of male and female reproductive system disorders. The aza-Gly (10) amide non-­mammalian analogs are yet other embodiments of the non-mammalian GnRH analogs provided as a part of the invention.
Children who lack functional spoken language are candidates for augmentative and alternative communication (AAC). Aided AAC and naturalistic interventions offer the potential to extend the communication functions demonstrated by children with autism spectrum disorder (ASD) who are nonspeaking. Related intervention research, however, has been limited, in that interventions have generally targeted a limited range of communication functions taught in highly structured, decontextualized environments. The aim of this study was to investigate the efficacy of an intervention that combined aided AAC with a naturalistic intervention - enhanced milieu teaching (AEMT) - to increase symbolic communication in children with autism spectrum disorder. Three children with autism spectrum disorder participated in a multiple probe design, in which a range of communication functions were targeted using the AEMT. Results showed increases in the use of symbolic communication from baseline to intervention phases, which were found to be statistically significant for two of the three children (phi 0.7-0.81; p < .001). Intervention outcomes were generalized to a communication partner not involved in the intervention and maintained over time for all children. The study provides preliminary evidence that communication functions beyond object requests could be taught using a systematic, multi-element approach implemented across activities.
Background: Circular RNAs have been reported to be involved in regulating the progression of sepsis and sepsis-associated damage. Herein, this work investigated whether circ_0033530 had roles in the process of septic acute lung injury (sepsis-ALI) and its associated mechanism. Methods: Lipopolysaccharide (LPS)-stimulated human lung fibroblasts MRC-5 were used to mimic the cell model of sepsis-ALI in vitro . Levels of genes and proteins were detected by quantitative real-time polymerase chain reaction and Western blotting. Functional experiments were conducted using 5-ethynyl-2'-deoxyuridine assay, Cell Counting Kit-8 assay, flow cytometry, and enzyme-linked immunosorbent assay. The interaction between miR-1184 and circ_0033530 or toll-like receptor 4 (TLR4) was confirmed by dual-luciferase reporter and RNA immunoprecipitation assays. Results: Circ_0033530 expression was lower in sepsis patients and LPS-induced fibroblasts than those in healthy control and untreated cells. Functionally, knockdown of circ_0033530 protected fibroblasts against LPS-induced proliferation arrest, apoptosis, and inflammatory response. Mechanistically, circ_0033530 acted as a sponge for miR-1184, and TLR4 RNA was targeted by miR-1184, indicating the circ_0033530/miR-1184/TLR4 axis. Further rescue experiments showed that circ_0033530 silencing-mediated growth inhibition and inflammation on fibroblasts were attenuated by miR-1184 downregulation or TLR4 upregulation. Conclusion: Circ_0033530 knockdown alleviated LPS-induced proliferation arrest, apoptosis, and inflammation in lung fibroblasts by miR-1184/TLR4 axis, and provided molecular theoretical basis for circ_0033530 on the pathogenesis of sepsis-ALI.
Iron chelation naïve participants received DFX-DT 20 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 5 to 10 mg/kg/day, with a maximum dose of 40 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose.
PURPOSE:To obtain a material for oral cavity application capable of effectively removing the bacterial plaque of healthy person and effective in preventing dental caries and periodontosis by using an alkaline protease and an alkalinizing agent as essential components. CONSTITUTION:The objective composition can be produced by compounding 0.0001-10wt.% of an alkaline protease, 0.01-30wt.% of an alkalinizing agent (e.g. sodium bicarbonate or zeolite 4A) and, as necessary, 0.0001-10wt.% of a bacteriolytic enzyme (e.g. N-acetylmuramidase) and proper amounts of conventional components. It is used in the form of dentifrice (e.g. toothpaste, tooth powder or liquid dentifrice), mouth wash, pasta for oral cavity, cream for gingival massage, tablet for gargle, troche, chewing gum, ice cream, whipped cream, etc.
Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
PURPOSE OF REVIEW: This review provides an overview of the role of microcirculation in cardiac arrest and postcardiac arrest syndrome through handheld intravital microscopy and biomarkers. It highlights the importance of microcirculatory dysfunction in postcardiac arrest outcomes and explores potential therapeutic targets.
RECENT FINDINGS: Sublingual microcirculation is impaired in the early stage of postarrest and is potentially associated with increased mortality. Recent work suggests that the proportion of perfused small vessels is predictive of mortality. Microcirculatory impairment is consistently found to be independent of macrohemodynamic parameters. Biomarkers of endothelial cell injury and endothelial glycocalyx degradation are elevated in postarrest settings and may predict mortality and clinical outcomes, warranting further studies. Recent studies of exploratory therapies targeting microcirculation have shown some promise in animal models but still require significant research.
SUMMARY: Although research continues to suggest the important role that microcirculation may play in postcardiac arrest syndrome and cardiac arrest outcomes, the existing studies are still limited to draw any definitive conclusions. Further research is needed to better understand microcirculatory changes and their significance to improve cardiac arrest care and outcomes.
Estrogens should not be used in individuals with any of the following conditions:

  1. Undiagnosed abnormal genital bleeding.
  2. Known, suspected or history of cancer of the breast except in appropriately selected patients being treated for metastatic disease.
  3. Known or suspected estrogen-dependent neoplasia.
  4. Active deep vein thrombosis, pulmonary embolism or history of these conditions.
  5. Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction).
  6. Liver dysfunction or disease.
  7. ESTRACE should not be used in patients with known hypersensitivity to its ingredients. ESTRACE tablets 2 mg, contain FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
  8. Known or suspected pregnancy. There is no indication for ESTRACE in pregnancy. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (See PRECAUTIONS.)